Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Apr 08, 2021 10:55am
95 Views
Post# 32956426

RE:RE:RE:RE:So far so good

RE:RE:RE:RE:So far so good I would think the PR  would come out on Saturday, or perhaps Monday, but it seems likely one will be produced. Better yet would also be the conference call some here have suggested since that would help draw investor interest to the situation much more so than a press release. Actually, the company needs to adjust to the times and commit to doing much more frequent investor calls as they navigate through the NASH and cancer trials. Don't hold your breath waiting for that, however, as they have never yet given almsot any indication they are adapting to the changed investor relations environment (the exception being the Water Tower Research call).

Lee430 wrote: Question, since they are presenting at the AACR on Satuday and assuming there will be at least something new of material importance should we expect a PR from them on Friday?  If so I am hoping IR really steps up the game for this oppertunity.


<< Previous
Bullboard Posts
Next >>